Clicky

Cantargia AB(CANTA)

Description: Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Disease Immunology Antibodies Antibody Autoimmunity Autoimmune And Inflammatory Disease Systemic Sclerosis Interleukin Myocarditis

Home Page: www.cantargia.com

Ideon Gateway
Lund, 223 63
Sweden
Phone: 46 4 62 75 62 60


Officers

Name Title
Mr. Goran Forsberg Chief Exec. Officer
Mr. Thoas Fioretos M.D., Ph.D. Founder & Independent Director
Mr. Marcus Järås Founder & Scientific Advisor
Mr. Kjell Sjöström Founder
Mr. Bengt Jondell Chief Financial Officer
Ms. Liselotte Larsson Chief Operating Officer
Nina Valkama Exec. Assistant of Admin. & Fin.
Adnan Deronic IP & Communications Mang.
Dr. Dominique Tersago Chief Medical Officer
Johanna Christensen Financial Controller

Exchange: ST

Country: SE

Currency: Swedish krone (kr)

Forward PE: 2.742
Trailing PE: 0
Price-to-Book MRQ: 1.1066
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 27
Back to stocks